Patents Assigned to Molecular Partners AG
-
Patent number: 11834504Abstract: The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g. acute myeloid leukaemia (AML), in a mammal, including a human.Type: GrantFiled: March 9, 2022Date of Patent: December 5, 2023Assignee: MOLECULAR PARTNERS AGInventors: Nina Reschke, Sebastian Grimm, Christian Reichen, Bernd Schlereth, Victor Levitsky, Matteo Bianchi
-
Patent number: 11578427Abstract: The present invention relates to designed ankyrin repeat domains with altered surface residues, as well as to proteins comprising such a designed ankyrin repeat domain, nucleic acids encoding such domains or proteins, methods of preparing such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: August 12, 2021Date of Patent: February 14, 2023Assignee: MOLECULAR PARTNERS AGInventors: Hans Kaspar Binz, Johannes Schilling, Patrik Forrer, Victor Levitsky, Natalia Venetz, Marcel Walser
-
Patent number: 11466062Abstract: The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.Type: GrantFiled: May 6, 2021Date of Patent: October 11, 2022Assignee: MOLECULAR PARTNERS AGInventors: Patrick Amstutz, Valerie Perrine Calabro, Marcel Walser
-
Patent number: 11453708Abstract: New designed ankyrin repeat proteins with binding specificity for HGF are described, as well as nucleic acids encoding such HGF binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: June 2, 2014Date of Patent: September 27, 2022Assignee: MOLECULAR PARTNERS AGInventors: Gaby Tresch, Talitha Bakker, Douglas Phillips, Frieder W. Merz, Kaspar H. Binz
-
Patent number: 11332501Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: November 2, 2018Date of Patent: May 17, 2022Assignee: MOLECULAR PARTNERS AGInventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Patent number: 10717772Abstract: New recombinant binding proteins, comprising designed ankyrin repeat domain(s) with binding specificity for HER2, and comprising designed ankyrin repeat domain(s) with binding specificity for serum albumin, are disclosed, as well as nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such recombinant binding proteins or nucleic acids and the use of such recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: September 20, 2017Date of Patent: July 21, 2020Assignee: Molecular Partners AGInventors: Clara Metz, Ulrike Fiedler, Ignacio Dolado, Heike Maria Strobel
-
Patent number: 10646542Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: November 14, 2017Date of Patent: May 12, 2020Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Patent number: 10370414Abstract: The present invention relates to a recombinant binding protein comprising at least a first and a second repeat domain, wherein each of said two repeat domains binds the extracellular region of HER2 and wherein said repeat domains are covalently linked.Type: GrantFiled: December 2, 2013Date of Patent: August 6, 2019Assignee: Molecular Partners AGInventors: Ulrike Fiedler, Ignacio Dolado, Heike Strobel
-
Patent number: 10322190Abstract: Improved N-terminal capping modules for designed Ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: June 23, 2017Date of Patent: June 18, 2019Assignee: Molecular Partners AGInventor: Hans Kaspar Binz
-
Patent number: 10155791Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: August 26, 2016Date of Patent: December 18, 2018Assignee: Molecular Partners AGInventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Patent number: 9849158Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: February 4, 2016Date of Patent: December 26, 2017Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Patent number: 9775912Abstract: New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.Type: GrantFiled: February 2, 2016Date of Patent: October 3, 2017Assignee: Molecular Partners AGInventors: Daniel Steiner, Hans Kaspar Binz, Maya Gulotti-Georgieva, Frieder W. Merz, Douglas Phillips, Ivo Sonderegger
-
Patent number: 9717802Abstract: Improved N-terminal capping modules for designed Ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: November 20, 2015Date of Patent: August 1, 2017Assignee: Molecular Partners AGInventor: Hans Kaspar Binz
-
Patent number: 9458211Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: April 1, 2016Date of Patent: October 4, 2016Assignee: Molecular Partners AGInventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Publication number: 20160251404Abstract: New designed ankyrin repeat proteins with binding specificity for HGF are described, as well as nucleic acids encoding such HGF binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: ApplicationFiled: June 2, 2014Publication date: September 1, 2016Applicant: MOLECULAR PARTNERS AGInventors: Gaby TRESCH, Talitha BAKKER, Douglas PHILLIPS, Frieder W. MERZ, Kaspar H. BINZ
-
Patent number: 9289466Abstract: The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: March 12, 2014Date of Patent: March 22, 2016Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Patent number: 9284361Abstract: New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.Type: GrantFiled: November 25, 2011Date of Patent: March 15, 2016Assignee: Molecular Partners AGInventors: Daniel Steiner, Hans Kaspar Binz, Maya Gulotti-Georgieva, Frieder W. Merz, Douglas Phillips, Ivo Sonderegger
-
Patent number: 9221892Abstract: Improved N-terminal capping modules for designed ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: November 25, 2011Date of Patent: December 29, 2015Assignee: Molecular Partners AGInventor: Hans Kaspar Binz
-
Publication number: 20150299265Abstract: The present invention relates to a recombinant binding protein comprising at least a first and a second repeat domain, wherein each of said two repeat domains binds the extracellular region of HER2 and wherein said repeat domains are covalently linked.Type: ApplicationFiled: December 2, 2013Publication date: October 22, 2015Applicant: Molecular Partners AGInventors: Ulrike Fiedler, Ignacio Dolado, Heike Strobel
-
Patent number: 9163070Abstract: New designed ankyrin repeat proteins with binding specificity for PDGF-BB are described, as well as nucleic acids encoding such PDGF binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: June 27, 2013Date of Patent: October 20, 2015Assignee: MOLECULAR PARTNERS AGInventor: Michael Baumann